A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious Puberty

Trial Profile

A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious Puberty

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2012

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Precocious puberty
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories; TAP Pharmaceutical Products
  • Most Recent Events

    • 01 May 2012 Primary endpoint 'Clinical-response-rate' has been met.
    • 05 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top